Biogen (BIIB) has been in the spotlight for several advancements, particularly relating to the company's higher-dose Spinraza and SMA drug, salanersen. The higher-dose Spinraza is believed to be a catalyst for SMA dominance and a pivotal part of Biogen's upcoming growth phase, with clinical data showing that the company's SMA treatment boasts an impressive 92% walking rate. Alongside this, Biogen's once-yearly SMA therapy termed Salanersen is advancing to Phase 3 following promising Phase 1 results. A 70% reduction in neurodegeneration markers was reported in a breakthrough discovery involving the drug. Asset management companies such as Robeco Institutional Asset Management B.V. and North Growth Management Ltd. are raising Biogen's stock, further boosting confidence and perception of BIIB's strong performance. The company has received multiple 'Buy' and 'Outperform' ratings from analysts. However, despite these achievements, Biogen's stock experienced a 45% decline and been rated 'Hold' by brokerages or labeled as a 'Risky Investment'. In the future, Biogen announced plans for a new Global Headquarters and Innovation Hub in Kendall Square. Investors are also closely monitoring the ongoing lawsuit and the FDA fast track designation for Alzheimer treatment.
Biogen BIIB News Analytics from Wed, 04 Sep 2024 07:00:00 GMT to Sat, 28 Jun 2025 14:05:10 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -2
